LALINDEN ADVISORS LP

Institutional investor · Portfolio as of Q2 2025

Top Holdings376 positions

Checking export access…
Activity:
274.6M$764.9M4.7%———
Increased
60
384.2M$503M3.1%———
Increased
65
362.6M$402.4M2.5%———
New
81
362.1M$378.4M2.3%———
Decreased
0
??LI AUTO INCDelisted
Bond
271.7M$323M2.0%——
13 qtrssince 2022-Q2
Increased
52
324.3M$322.6M2.0%———
Increased
68
181.4M$291.1M1.8%———
Increased
50
278.2M$290.4M1.8%———
Increased
51
242.8M$251.3M1.5%——
10 qtrssince 2023-Q1
Increased
48
93.3M$238.2M1.5%———
Increased
48
243.9M$218.9M1.3%———
Decreased
0
118M$216.5M1.3%———
New
70
??MKS INC.
Bond
217.1M$214.7M1.3%———
New
70
99M$212.6M1.3%———
New
70
284.5M$208.8M1.3%———
Increased
75
156.3M$200.3M1.2%———
Decreased
0
??ASCENDIS PHARMA ADelisted
Bond
154.7M$193.9M1.2%———
Decreased
0
??FIVE9 INC
Bond
221.4M$193.8M1.2%———
Decreased
0
133.7M$191.7M1.2%———
Increased
51
175.7M$186.7M1.1%———
Increased
48
$16.3B
AUM
376
Positions
Q2 2025
Filing
HI score · 2.0/5
Quarterly 13F Value Change
+0%Q2'23$9.5B+2%Q3'23$9.7B+8%Q4'23$10.5B+15%Q4'24$12.1B+22%Q1'25$14.7B+10%Q2'25$16.3B
Activity profile
$ moved · Q2'25
New41%Increased18%Decreased15%Exited26%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 4.0 quarters
<1Q33%1-4Q33%1-2Y11%2Y+23%

LINDEN ADVISORS LP manages $16.3B across 376 positions as of Q2 2025. Top holdings: STRATEGY INC (4.7%), COINBASE GLOBAL INC (3.1%), TRIP COM GROUP LTD (2.5%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2/5.0.

Q2 2025 Summary

Active quarter - 131 new positions, 62 exits, 57 increased. No standout high-conviction moves this quarter. Portfolio: $16.3B across 376 positions.

Top holdings by portfolio weight

Total AUM$16B
STRATEGY INC4.70%
COINBASE GLO3.09%
TRIP COM GRO2.47%
SUPER MICRO 2.32%
LI AUTO INC1.98%
ZTO EXPRESS 1.98%
TRANSMEDICS 1.79%
LIBERTY MEDI1.78%
LUMENTUM HLD1.54%
MAKEMYTRIP L1.46%
Other1.34%

Portfolio allocation by GICS sector

Sectors8
Financial Services51.92%
Unknown22.56%
Technology12.80%
Utilities9.62%
Basic Materials1.43%
Consumer Cyclical1.31%
Communication Services0.19%
Healthcare0.17%

Behavioral investing profile

Checking access…
Diversified Scout
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(2.0 / 5.0)
Holdings P&L57
Conviction31
Concentration37
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BR10806XAD4BRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+151.4M shares+$192.5M
7Q
VI928298AR9VISHAY INTERTECHNOLOGY INC
Q4 2024 → Q2 2026+353.9M shares+$770.5M
4Q
CO19459JAC8COLLEGIUM PHARMACEUTICAL INC
Q3 2025 → Q2 2026+26.6M shares+$50.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used